It is, thus, not surprising that V1b receptor antagonists, inhibiting AVP and CRH-induced ACTH release, have raised experimental interest as potential agents for the treatment of stress-related disorders and MDD (95). This evidence concerns the gene AVPR1B and major depressive disorder.